0.9% Sodium Chloride injection may be used in most cases.



Similar documents
Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Anticoagulant therapy

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

2.5mg SC daily. INR target mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

Guideline for Anticoagulation and Prophylaxis Using Low Molecular Weight Heparin (LMWH) in Adult Inpatients

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Anticoagulation guidelines for chronic and acute hemodialysis patients

Anticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h

PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2013

Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Heparin Induced Thrombocytopenia

Confirmed Deep Vein Thrombosis (DVT)

Venous and Lymphatic Disorders

New Oral Anticoagulants. How safe are they outside the trials?

East Kent Prescribing Group

Venous Thromboembolic Treatment Guidelines

DVT/PE Management with Rivaroxaban (Xarelto)

NHS FIFE WIDE POLICY - HAEMATOLOGY MANAGEMENT OF ANTICOAGULATION THERAPY DURING MAJOR AND MINOR ELECTIVE SURGERY

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Cardiovascular Disease

CLINICAL PRACTICE GUIDELINE: MOBILITY WITH A DEEP VEIN THROMBOSIS (DVT) Page 1 of 10

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

ABOUT XARELTO CLINICAL STUDIES

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Investor News. Not intended for U.S. and UK media

Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.

CDEC RECORD OF ADVICE

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC

Time of Offset of Action The Trial

Common Drug Review Pharmacoeconomic Review Report

Reversal of Anticoagulants at UCDMC

CDEC FINAL RECOMMENDATION

Low Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice

xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare

National Patient Safety Goals Effective January 1, 2015

Oxford Anticoagulation & Thrombosis Service Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

Clinical Study Synopsis

3/3/2015. Patrick Cobb, MD, FACP March 2015

National Patient Safety Goals Effective January 1, 2015

Thrombosis and Hemostasis

Anticoagulation at the end of life. Rhona Maclean

Introduction. Background to this event. Raising awareness 09/11/2015

Guidelines for diagnosis and management of acute pulmonary embolism

ACCP MODEL PRACTICE. A Pharmacist-Staffed Inpatient Antithrombosis Service. American College of Clinical Pharmacy. William E. Dager, Pharm.D.

PRACTICE GUIDELINES FOR ANTICOAGULATION MANAGEMENT

Antithrombotic therapy

Guideline for managing patients on a factor Xa inhibitor Apixaban (Eliquis ) or Rivaroxaban (Xarelto )

To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism.

The new oral anticoagulants & the future of haemostasis laboratory testing. Alcohol: the good, the bad and the ugly

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Dabigatran (Pradaxa) Guidelines

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

National Guidance and New Protocols

Duration of Dual Antiplatelet Therapy After Coronary Stenting

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Updates to the Alberta Human Services Drug Benefit Supplement

Are there sufficient indications for switching to new anticoagulant agents

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

FDA Approved Oral Anticoagulants

New Anticoagulants: When and Why Should I Use Them? Disclosures

The author has no disclosures

Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )

Randomized, double-blind, parallel-group, multicenter, doubledummy

National Guidance and New Protocols

SUFFOLK COUNTY COMMUNITY COLLEGE NURSING DEPARTMENT MEDICATION ADMINISTRATION TEST NR 40 Practice test questions READ INSTRUCTIONS CAREFULLY

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery

Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:

AHA/ASA Ischemic Stroke Performance Measures

Updates to the Alberta Drug Benefit List. Effective January 1, 2016

Continuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Lower extremity DVT See Page 3. Clinical Suspicion of VTE. Pulmonary embolism (PE) See Page 4

Chapter 15. Reconstitution and Dosages Measured in Units. Copyright 2012, 2007 Mosby, Inc., an affiliate of Elsevier Inc. All rights reserved.

Guideline for managing patients on Dabigatran (Pradaxa ) Statewide

Pathway for the management of DVT in primary Care

Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014

Transcription:

Table 2. Alternatives to Heparin Sodium in Selected Situations 12-14 Situation Alternative Dose Maintain patency of peripheral venous catheters* 21-26 0.9% Sodium Chloride injection may be used in most cases. medication administration 21-26 Maintain patency of central venous catheters* 22,27,28 NOTE: Heparin sodium (1 10 units/ml) may be needed in small children and infants; their catheters may clot more often than an adult s due to smaller vein size and catheter bore. Intermittent: 0.9% Sodium Chloride injection Maintenance: flush every 8 12 hours when the device is not in use 21-26 medication administration. 22,27,28 Tunneled catheter or implantable port catheter Maintain patency of central venous catheters* 22,27,28 Percutaneous central venous catheter or peripherally-inserted central venous catheter Abdominal surgery Maintenance: 0.9% Sodium Chloride injection Intermittent: no alternative; recommend conservation of heparin sodium. Maintenance: no alternative; recommend conservation of heparin sodium. NOTE: There are no published data on the use of 0.9% Sodium Chloride injection alone for these catheters., Maintenance: flush every 8 24 hours, depending on the type of catheter used. Tunneled catheters may be flushed once daily to once weekly; implantable port catheters may be flushed after each use or every 30 days. 22,27,28 medication administration with 0.9% Sodium Chloride injection 2.5 5 ml. May be followed by heparin (10 100 unit/ml) 1 5 ml depending on the type of catheter used. 22,27,28 Maintenance: flush with heparin (10 100 unit/ml) 1 5 ml every 8 24 hours, depending on the type of catheter used. 22,27,28 2,500 5,000 units subcutaneously every day, starting before surgery and continuing for 5 10 days 40 mg subcutaneously every day, starting before surgery and continuing for 7 10 days 2.5 mg subcutaneously every

Hip replacement surgery, 2,500 5,000 units subcutaneously every day, starting before surgery and continued 5 10 days 30 mg subcutaneously every 12 hours, starting 12 24 hours after surgery and continuing for 7 10 days An alternative regimen is enoxaparin 40 mg subcutaneously every day, starting before surgery and continuing 3 weeks 2.5 mg subcutaneously every Knee-replacement surgery Acute illness with mobility restriction DVT without PE (outpatient therapy), 30 mg subcutaneously every 12 hours, starting 12 24 hours after surgery and continuing for 7 10 days 2.5 mg subcutaneously every 5,000 units subcutaneously every day for 12 14 days. 40 mg subcutaneously every day for 6 to 14 days. 1 mg/kg subcutaneously every 12 hours Note: Start warfarin therapy when appropriate, usually within 3 days of starting LMWH; continue LMWH therapy until INR is in therapeutic range (usually an additional 5 7 days).

DVT with PE (inpatient therapy), 1 mg/kg subcutaneously every 12 hours, or 1.5 mg/kg subcutaneously every day. 5 10 mg subcutaneously every day, based on weight: Weight < 50 kg: 5 mg/day Weight 50 100 kg: 7.5 mg/day Weight > 100 kg: 10 mg/day DVT without PE in cancer patients DVT with PE in cancer patients Acute myocardial infarction with ST-segment elevation Myocardial infarction, non Q-wave Note: Start warfarin therapy when appropriate, usually within 3 days of starting injectable anticoagulant; continue injectable anticoagulant therapy until INR is in therapeutic range (usually an additional 5 7 days). 200 units/kg subcutaneously once daily for 30 days, then 150 units/kg subcutaneously once daily for 5 additional months. Do not exceed 18,000 units/dose. 200 units/kg subcutaneously once daily for 30 days, then 150 units/kg subcutaneously once daily for 5 additional months. Do not exceed 18,000 units/dose. 30 mg IV plus 1 mg/kg subcutaneously initially, then 1 mg/kg every with aspirin 75 325 mg/day orally. Do not exceed 100 mg/dose for first two doses only, remainder of doses are weight-based. 120 units/kg subcutaneously every 12 hours for 5 8 days, given concurrently with aspirin 75 165 mg/day orally. Do not exceed 10,000 units/dose. 1 mg/kg subcutaneously every with aspirin 100 325 mg/day orally.

Unstable angina Bivalirudin, Bivalirudin 0.75 mg/kg IV bolus, followed by 1.755 mg/kg/hour for the duration of the PTCA procedure and for up to 4 hours after the procedure. After the 4-hour infusion, may give an 0.2 mg/kg/hr infusion for up to 20 hours. Start bivalirudin therapy just before PTCA procedure. Give concurrently with aspirin 300 325 mg/day orally. 120 units/kg subcutaneously every 12 hours for 5 8 days, given concurrently with aspirin 75 165 mg/day orally. Do not exceed 10,000 units/dose. Systemic thrombosis or rapid anticoagulation required Manage patients as if they have heparin-induced thrombocytopenia. Low molecular weight heparins are porcinederived. Consultations with Hematologists or clinicians who specialize in anticoagulation may be helpful. 1 mg/kg subcutaneously every with aspirin 100 325 mg/day orally. Rapid Anticoagulation 29-31 Initial dose of 2 mcg/kg/min adjusted to maintain aptt 1.5 3 times the baseline value. For patients with hepatic dysfunction, use an initial dose of 0.5 mcg/kg/min or avoid use when possible. Maintain patency of dialysis catheters Alternatives may include: Data are limited to case reports and 1 small clinical trial (alteplase) Alteplase Begin warfarin therapy as soon as clinically possible. is the preferred agent for patients with renal dysfunction. Clearly label all catheters with the agent and dose instilled into each lumen, the date instilled, and a warning DO NOT FLUSH. Alteplase 1.5 2 mg instilled into each catheter lumen at the end of dialysis. 32,33

No anticoagulation No anticoagulation Hemodialysis without anticoagulation generally requires closer nursing observation During active hemodialysis and filter flushes every 15 30 minutes. 34-36 Clinicians should note that data for using argatroban during dialysis are limited to small case reports. Extracorporeal Administration 10 mg into the circuit at the start of hemodialysis followed by a continuous infusion of 5 40 mg/hr into the circuit until dialysis is complete. 37-40 is the preferred agent in patients with renal dysfunction. Abbreviations: aptt= activated partial thromboplastin time; CVVHD = continuous venovenous hemodialysis; DVT = deep vein thrombosis; INR = international normalized ratio; IV = intravenous; LMWH = low molecular weight heparin; PE = pulmonary embolism; PTCA = percutaneous transluminal coronary angiography. *Heparin sodium 10 unit/ml and 100 unit/ml flush solutions are available from APP, Hospira, Covidien, Medefil, and BD. 4,5,8-10